Oral Factor XIIa Inhibitor (KVD824)

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a mission-driven biotech focused on developing oral therapies for rare diseases with significant unmet need, beginning with hereditary angioedema (HAE). The company has successfully transitioned to a commercial entity with the FDA approval and launch of EKTERLY®, a first-in-class oral on-demand therapy for HAE attacks. Its strategy leverages a proprietary small molecule platform targeting the kallikrein-kinin system to expand its HAE portfolio into prophylaxis and explore new indications in thrombosis and inflammation.

Therapeutic Areas